JP4532486B2 - Ｒａ抗原ペプチド - Google Patents

Ｒａ抗原ペプチド Download PDF

Info

Publication number
JP4532486B2
JP4532486B2 JP2006522303A JP2006522303A JP4532486B2 JP 4532486 B2 JP4532486 B2 JP 4532486B2 JP 2006522303 A JP2006522303 A JP 2006522303A JP 2006522303 A JP2006522303 A JP 2006522303A JP 4532486 B2 JP4532486 B2 JP 4532486B2
Authority
JP
Japan
Prior art keywords
seq
peptide
peptides
protein
mhc class
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006522303A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007527226A (ja
Inventor
ニコラス バーンテニス
ゲリット ブールマン
ハラルド クロプショファー
ベルンド クリスチャン ミューラー
セバスチャン トーマス スピンデルドラー
アン ボークト
ワーナー ゾルグ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2007527226A publication Critical patent/JP2007527226A/ja
Application granted granted Critical
Publication of JP4532486B2 publication Critical patent/JP4532486B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Rehabilitation Therapy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006522303A 2003-08-07 2004-07-30 Ｒａ抗原ペプチド Expired - Fee Related JP4532486B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03017551 2003-08-07
PCT/EP2004/008609 WO2005014622A2 (en) 2003-08-07 2004-07-30 Ra antigenic peptides

Publications (2)

Publication Number Publication Date
JP2007527226A JP2007527226A (ja) 2007-09-27
JP4532486B2 true JP4532486B2 (ja) 2010-08-25

Family

ID=34130049

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006522303A Expired - Fee Related JP4532486B2 (ja) 2003-08-07 2004-07-30 Ｒａ抗原ペプチド

Country Status (14)

Country Link
US (1) US20080193457A1 (ru)
EP (1) EP1654272B1 (ru)
JP (1) JP4532486B2 (ru)
KR (1) KR100769338B1 (ru)
CN (1) CN100584858C (ru)
AT (1) ATE442377T1 (ru)
AU (1) AU2004263303A1 (ru)
BR (1) BRPI0412668A (ru)
CA (1) CA2532721A1 (ru)
DE (1) DE602004023096D1 (ru)
ES (1) ES2330748T3 (ru)
MX (1) MXPA06001326A (ru)
RU (1) RU2359974C2 (ru)
WO (1) WO2005014622A2 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1715343B1 (en) 2005-04-20 2009-12-09 F. Hoffmann-La Roche Ag Method for the identification of epitopes related to immunogenicity in biopharmaceuticals
US8821851B2 (en) 2006-03-23 2014-09-02 The General Hospital Corporation Inflammation-inhibitory serum factors and uses thereof
FR2900155B1 (fr) * 2006-04-21 2008-06-27 Diana Naturals Sa Hydrolisat de cartilage aviaire, procede d'obtention et utilisations
EP2076544A4 (en) * 2006-09-25 2009-11-11 Sj Biomed Inc ANTI-OBESITY IMMONOGENIC HYBRID POLYPEPTIDES AND ANTI-OBESITY VACCINE COMPOSITION COMPRISING THE SAME
JP5555846B2 (ja) * 2007-03-30 2014-07-23 国立大学法人山口大学 急性中枢神経障害の予後判定方法
EP2056110A1 (en) * 2007-10-31 2009-05-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Biomarker for the prediction of responsiveness to an anti-tumour necrosis factor alpha (TNF) treatment
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP3169343B1 (en) 2014-07-15 2020-03-25 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Isolated polypeptides of cd44 and uses thereof
SG11202011460YA (en) * 2018-06-25 2020-12-30 Univ Washington De novo design of potent and selective interleukin mimetics
CN111748580B (zh) * 2019-03-28 2022-09-13 百奥泰生物制药股份有限公司 一种检测免疫检查点抗体活性的方法
KR20220044683A (ko) * 2019-08-09 2022-04-11 프라운호퍼 게젤샤프트 쭈르 푀르데룽 데어 안겐반텐 포르슝 에. 베. 관절염 치료를 위한 hla-dr/cii 펩티드 복합체
WO2022188025A1 (zh) * 2021-03-09 2022-09-15 台北医学大学 抗修饰胜肽抗体及其检测关节炎之方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9204780D0 (en) * 1992-03-05 1992-04-15 Smith Geoffrey L Vaccinia vectors,vaccinia genes,and expression products thereof;pharmaceuticals,reagents and methods
AU2001233114A1 (en) * 2000-02-04 2001-08-14 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
EP1478772A2 (en) * 2001-08-14 2004-11-24 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
WO2003058021A2 (de) * 2002-01-11 2003-07-17 Xantos Biomedicine Ag Neue apoptose-induzierende dna-sequenzen
ATE474851T1 (de) * 2002-10-02 2010-08-15 Hoffmann La Roche Verfahren zur identifizierung antigener peptide

Also Published As

Publication number Publication date
BRPI0412668A (pt) 2006-09-26
WO2005014622A3 (en) 2005-05-06
ATE442377T1 (de) 2009-09-15
JP2007527226A (ja) 2007-09-27
CN100584858C (zh) 2010-01-27
CA2532721A1 (en) 2005-02-17
CN1845936A (zh) 2006-10-11
MXPA06001326A (es) 2006-05-04
RU2006106729A (ru) 2007-09-20
EP1654272A2 (en) 2006-05-10
DE602004023096D1 (de) 2009-10-22
US20080193457A1 (en) 2008-08-14
WO2005014622A2 (en) 2005-02-17
EP1654272B1 (en) 2009-09-09
AU2004263303A1 (en) 2005-02-17
ES2330748T3 (es) 2009-12-15
KR100769338B1 (ko) 2007-10-24
KR20060033923A (ko) 2006-04-20
RU2359974C2 (ru) 2009-06-27

Similar Documents

Publication Publication Date Title
Wucherpfennig et al. Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes.
AU2004216925B2 (en) Peptides associated with HLA-DR MHC class II molecules involved in autoimmune diseases
Van Stipdonk et al. T cells discriminate between differentially phosphorylated forms of alphaB-crystallin, a major central nervous system myelin antigen.
JP4620339B2 (ja) 抗原ペプチドの同定法
Kobayashi et al. Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen
Chiu et al. The majority of H2-M3 is retained intracellularly in a peptide-receptive state and traffics to the cell surface in the presence of N-formylated peptides
JP4532486B2 (ja) Ｒａ抗原ペプチド
JP3755894B2 (ja) 自己免疫疾患の免疫療法に用いるための、自己抗原から誘導された新規なペプチド
WO2009090651A2 (en) Major histocompatibility complex hla-b2705 ligands useful for therapy and diagnosis
US20210162019A1 (en) Immunodominant proteins and fragments in multiple sclerosis
EP1575529A2 (en) Peptides and methods of screening immunogenic peptide vaccines against alzheimer's disease
US20110159021A1 (en) Xbp1, cd138, and cs1 peptides
JP2006525813A (ja) １型糖尿病において罹患性病原性ｔ細胞により標的とされる抗原ならびにこれの使用
US6562943B1 (en) Peptide epitopes recognized by disease promoting CD4+ T lymphocytes
Calviño-Sampedro et al. Naturally presented HLA class I–restricted epitopes from the neurotrophic factor S100-β are targets of the autoimmune response in type 1 diabetes
US20090023630A1 (en) Methods and Means for Use in Diagnostics and Treatment of Diabetes
CLIP TER

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090508

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090811

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100401

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100423

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100524

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100610

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130618

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees